Montelukast Generics [uk]

Montelukast, the active ingredient in Montelukast Generics [uk], is a leukotriene receptor antagonist presented as an oral tablet for oral use. It is used to manage asthma, allergic rhinitis and exercise‑induced bronchoconstriction in adults and children. GNH USA supplies Montelukast Generics [uk] as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast acts on leukotriene pathways to control chronic airway and nasal inflammation. - Asthma (maintenance therapy): reduces frequency and severity of asthma attacks and improves overall lung function. - Allergic rhinitis: alleviates nasal congestion, sneezing and itchy eyes caused by seasonal allergens. - Exercise‑induced bronchoconstriction: prevents airway narrowing during physical activity, allowing better exercise tolerance.

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity, often transient. - Upper respiratory tract infection: symptoms such as sore throat or nasal congestion. - Abdominal pain: occasional discomfort or cramping. - Cough: non‑productive cough may be reported.

Serious or Rare Side Effects: - Neuropsychiatric events: agitation, depression, or rare suicidal thoughts. - Allergic reactions: rash, urticaria, or angioedema. - Hepatic dysfunction: elevated liver enzymes in rare cases. - Blood dyscrasias: rare reports of neutropenia or eosinophilia.

Before initiating therapy, consider the following precautions. - Pregnancy: Category B; use only if clearly needed after risk‑benefit assessment. - Breastfeeding: Small amounts excreted in milk; weigh benefits to infant against maternal need. - Hepatic impairment: Use with caution; monitor liver function if clinically indicated. - Concomitant asthma therapy: Do not discontinue inhaled corticosteroids without medical advice. - Pediatric use: Safety and efficacy established for specific age groups; follow prescriber guidance. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Montelukast may interact with several medicines; monitor accordingly.

Major Interactions (Avoid): - Phenobarbital or rifampicin: may reduce montelukast plasma concentrations, decreasing efficacy. - Strong CYP3A4 inhibitors (e.g., ketoconazole): potential increase in exposure, though clinical significance is low.

Moderate Interactions (Monitor Closely): - Warfarin: occasional reports of altered INR; monitor coagulation parameters. - Beta‑agonists: additive bronchodilatory effect; assess symptom control. - Antidepressants (SSRIs): monitor for neuropsychiatric symptoms when combined.